Dumiva Dispersible 120mg/60 mg TABLETS
PDF Leaflet Revision Date: 17 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in children from 3 months to 12 years.
Dosage (summary)
Children 3-12 years: 1-3 tablets daily based on weight.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding.
Key Drug Interactions
- Ethanol may increase abacavir AUC by 41%
- Trimethoprim increases lamivudine exposure by 40%
Contraindications
- Hypersensitivity to abacavir or lamivudine
- Severe hepatic impairment
- Severe renal impairment
- Pregnancy and breastfeeding
Common side effects
- Hypersensitivity reactions
- Nausea
- Vomiting
- Diarrhoea
- Rash
- Fever
Counselling Points
- Inform about hypersensitivity risks.
- Do not restart if hypersensitivity occurs.
- Regular monitoring during the first two months.
Serious warnings
- Risk of lactic acidosis
- Severe hypersensitivity reactions
- Potential for mitochondrial dysfunction
Important Disclaimer
The Dumiva Dispersible 120mg/60 mg TABLETS professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
